Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Non-Current Deffered Revenue (2023 - 2025)

Beta Bionics (BBNX) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 77.26% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 77.26% year-over-year, with the annual reading at $3.3 million for FY2025, 77.26% up from the prior year.
  • Non-Current Deffered Revenue hit $3.3 million in Q4 2025 for Beta Bionics, up from $3.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.3 million in Q4 2025 to a low of $255000.0 in Q4 2023.
  • Historically, Non-Current Deffered Revenue has averaged $2.2 million across 3 years, with a median of $2.5 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 629.41% in 2024 and later skyrocketed 77.26% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $255000.0 in 2023, then skyrocketed by 629.41% to $1.9 million in 2024, then skyrocketed by 77.26% to $3.3 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for BBNX at $3.3 million in Q4 2025, $3.0 million in Q3 2025, and $2.7 million in Q2 2025.